Machado Bergamaschi, M., Helena Costa Queiroz, R., Waldo Zuardi, A., & Alexandre S. Crippa, J. (2011). Safety and Side Effects of Cannabidiol, a Cannabis sativa Constituent. Current Drug Safety, 6(4), 237–249. https://doi.org/10.2174/157488611798280924
Cunha, J. M., Carlini, E., Pereira, A. E., Ramos, O. L., Pimentel, C., Gagliardi, R., . . . Mechoulam, R. (1980). Chronic Administration of Cannabidiol to Healthy Volunteers and Epileptic Patients. Pharmacology, 21(3), 175–185. https://doi.org/10.1159/000137430
Pamplona, F. A., da Silva, L. R., & Coan, A. C. (2018). Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis. Frontiers in Neurology, 9. Published. https://doi.org/10.3389/fneur.2018.00759
Zuardi, A. W., Morais, S. L., Guimarães, F. S., & Mechoulam, R. (1995). Antipsychotic effect of cannabidiol. The Journal of clinical psychiatry, 56(10), 485–486.
Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., . . . Koethe, D. (2012). Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Translational Psychiatry, 2(3), e94. https://doi.org/10.1038/tp.2012.15
Blessing, E. M., Steenkamp, M. M., Manzanares, J., & Marmar, C. R. (2015). Cannabidiol as a Potential Treatment for Anxiety Disorders. Neurotherapeutics, 12(4), 825–836. https://doi.org/10.1007/s13311-015-0387-1
Cuñetti, L., Manzo, L., Peyraube, R., Arnaiz, J., Curi, L., & Orihuela, S. (2018). Chronic Pain Treatment With Cannabidiol in Kidney Transplant Patients in Uruguay. Transplantation Proceedings, 50(2), 461–464. https://doi.org/10.1016/j.transproceed.2017.12.042
CARLINI, E. A., & CUNHA, J. M. (1981). Hypnotic and Antiepileptic Effects of Cannabidiol. The Journal of Clinical Pharmacology, 21(S1), 417S-427S. https://doi.org/10.1002/j.1552-4604.1981.tb02622.x
Russo, E. B. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology, 163(7), 1344–1364. https://doi.org/10.1111/j.1476-5381.2011.01238.x
Ben-Shabat, S., Fride, E., Sheskin, T., Tamiri, T., Rhee, M. H., Vogel, Z., . . . Mechoulam, R. (1998). An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. European Journal of Pharmacology, 353(1), 23–31. https://doi.org/10.1016/s0014-2999(98)00392-6
Millar, S. A., Stone, N. L., Yates, A. S., & O’Sullivan, S. E. (2018). A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans. Frontiers in Pharmacology, 9. Published. https://doi.org/10.3389/fphar.2018.01365
Zgair, A., Wong, J. C., Lee, J. B., Mistry, J., Sivak, O., Wasan, K. M., Hennig, I. M., Barrett, D. A., Constantinescu, C. S., Fischer, P. M., & Gershkovich, P. (2016). Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines. American journal of translational research, 8(8), 3448–3459.
Stott, C. G., White, L., Wright, S., Wilbraham, D., & Guy, G. W. (2012). A phase I study to assess the effect of food on the single dose bioavailability of the THC/CBD oromucosal spray. European Journal of Clinical Pharmacology, 69(4), 825–834. https://doi.org/10.1007/s00228-012-1393-4
Eichler, M., Spinedi, L., Unfer-Grauwiler, S., Bodmer, M., Surber, C., Luedi, M., & Drewe, J. (2012). Heat Exposure ofCannabis sativaExtracts Affects the Pharmacokinetic and Metabolic Profile in Healthy Male Subjects. Planta Medica, 78(07), 686–691. https://doi.org/10.1055/s-0031-1298334